Search the Newsreel

Genscript Highlights Legend Biotech’s Q2 Results and Cautions Investors

Riot, NIQ surge, On Holding tumbles premarket

Investing.com - U.S. stock futures were little changed on Tuesday, as fading hopes for a deal to reopen the Strait of Hormuz kept oil prices elevated, while investors looked ahead to key U.S. inflation data for fresh clues on the Federal Reserve's interest rate …

Riot Stock Soars as It Lands a $9.1 Billion AI Cloud Deal

This article first appeared on GuruFocus. Riot Platforms (NASDAQ:RIOT), a Bitcoin miner that has moved into selling AI data-center capacity, rose 18.87% premarket after striking a 20-year deal to supply 191 megawatts of computing to Anthropic from its Rockdale, Texas campus, according to Bloomberg, …

Earnings call transcript: Legend Biotech tops Q2 2026 estimates as stock rises 5%

Legend Biotech reported stronger-than-expected Q2 2026 results, achieving its first quarter of company-wide profitability with adjusted earnings of $0.16 per share and revenue of $387.5 million, significantly beating analyst estimates. The company's lead CAR-T therapy, CARVYKTI, saw worldwide net trade sales increase 50% year-over-year, …

Form 8K PDS Biotechnology Corp For: 11 August By Investing.com

This article announces the filing of a Form 8K by PDS Biotechnology Corp for August 11, as reported by Investing.com. It provides a brief update on company filings without further details on the content of the Form 8K. The article appears to be a …

PDS0301 Data Show 80% 24-Month Survival With Liver Metastases

PDS Biotechnology (Nasdaq: PDSB) announced a strategic refocus, prioritizing its tumor-targeted IL-12 immunocytokine PDS0301 and discontinuing internal investment in the PDS0101 Phase 3 VERSATILE-003 trial, instead seeking strategic partnerships for PDS0101. This decision follows promising Phase 2 data for PDS0301 in metastatic colorectal cancer …

Ex-Legend CEO takes helm at biotech startup scouring the globe for drugs

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. The CEO who helped guide development of the top-selling cell therapy for multiple myeloma will take the reins of a young startup …

What is HC Wainwright's Forecast for ARTV Q3 Earnings?

Legend Biotech stock rises 5% on earnings and revenue beat

Pipette dropping liquid into a test tube ©Adobe Stock Images Legend Biotech Corporation (NASDAQ:LEGN) shares gained 5.5% in pre-market trading on Tuesday after the pharmaceutical company delivered better-than-expected second-quarter earnings and revenue, supported by continued growth in CARVYKTI sales. Adjusted earnings came in at …

RBC Adjusts PT on Lakefront Biotherapeutics to $26 From $28, Keeps Sector Perform Rating

RBC has lowered its price target for Lakefront Biotherapeutics (LKFT) to $26 from $28, while maintaining a "Sector Perform" rating on the stock. This adjustment reflects a revised outlook from the analyst firm. The article, published on MarketScreener, notes that details are reserved for …

Legend Biotech Reports Second Quarter 2026 Results and Recent Highlights

Legend Biotech USA Inc. CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales increased 50% versus second quarter of 2025 to approximately $657 million Expanded CARVYKTI® availability to 348 global sites and 19 global markets with the launch of Ireland Achieved first clinical proof-of-concept for LB2501, …

Sana Biotechnology (SANA) Is Up 13.5% After Narrower Losses And Mayo Clinic Equity Deal - What's Changed

Sana Biotechnology (SANA) reported narrower losses in Q2 2026 and announced a US$25 million equity deal with the Mayo Clinic, contributing to a 13.5% stock increase. The company also made progress in its clinical programs and unveiled promising data for its UP421 cell therapy. …

Why Is Riot Platforms Stock Soaring Tuesday? - Riot Platforms (NASDAQ:RIOT)

Adaptive Biotechnologies Corp (ADPT) Stock Analysis: Navigating the Growth Path with a 21.5% Revenue Surge

Adaptive Biotechnologies Corp (ADPT) is a commercial-stage company leveraging its immune medicine platform for diagnostics and treatment, showing a 21.5% revenue growth. Despite current losses and a negative Forward P/E, the company has a strong market capitalization of $4.05 billion and positive analyst sentiment …

Hennion & Walsh Asset Management Inc. Grows Stock Position in Iovance Biotherapeutics, Inc. $IOVA

Hennion & Walsh Asset Management Inc. significantly increased its stake in Iovance Biotherapeutics (NASDAQ:IOVA) by 100% in the second quarter, now holding 818,913 shares valued at $3.4 million. This move comes as Iovance Biotherapeutics reported strong quarterly revenue growth of 65.7% year-over-year, beating analyst …

Why Did Adaptive Biotechnologies (ADPT) Move After Its Latest Update?

Riot stock surges after securing 20-year Anthropic AI infrastructure agreement

Riot Platforms saw its shares surge over 20% in pre-market trading after announcing a 20-year, $9.1 billion agreement with Anthropic to provide AI computing capacity. This deal highlights an industry-wide shift from bitcoin mining to offering AI infrastructure, leveraging existing power-rich data centers. The …

Riot Platforms reports Q2 results

* Riot Platforms press release [https://seekingalpha.com/pr/20607036-riot-reschedules-second-quarter-2026-earnings-conference-call] (RIOT [https://seekingalpha.com/symbol/RIOT]): Q2 GAAP EPS of -$0.68 misses by $0.39. * Revenue of $174.2M (+13.9% Y/Y) beats by $21.32M. * Data Center revenue of $23.2 million for the quarter, comprised of $4.9 million in operating lease revenue and …

Adaptive Biotechnologies stock hits 52-week high at 25.04 USD By Investing.com

Adaptive Biotechnologies (ADPT) stock has reached a 52-week high of $25.04, reflecting a 104% increase over the past year and underscoring strong performance in the biotechnology sector. The company's market capitalization is now $3.95 billion, with 50% revenue growth, indicating strong investor confidence. This …

Windlas Biotech Standalone June 2026 Net Sales at Rs 248.10 crore, up 18.09% Y-o-Y

Veraxa Biotech AG Ord Shs (VRXA) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Veraxa Biotech AG Ord Shs (VRXA), detailing its future EPS and Revenue Growth Estimates. It includes current stock performance data, market capitalization, and a peer comparison with other biotechnology and medical research companies. The financial forecasting sections …

Vir Biotechnology, Inc. (NASDAQ:VIR) Receives Average Recommendation of "Moderate Buy" from Brokerages

Vir Biotechnology, Inc. (NASDAQ:VIR) has an average "Moderate Buy" rating from analysts, with a consensus 12-month price target of $20.63, significantly higher than its current price of $8.89. The company recently reported strong quarterly earnings, beating revenue and EPS estimates, despite a negative net …

VAC Company (NYSE: VAC) details planned common stock sale and past grants

A holder of VAC common stock has filed a notice to sell securities through Fidelity Brokerage Services LLC, involving 5,194 shares with a reported transaction amount of $602,504.00, scheduled for trading on the NYSE on August 10, 2026. The filing also details previous restricted …

SAB Biotherapeutics, Inc. (NASDAQ:SABS) Receives Consensus Rating of "Moderate Buy" from Brokerages

SAB Biotherapeutics, Inc. (NASDAQ:SABS) has received a consensus "Moderate Buy" rating from eleven brokerages, with an average 12-month price target of $12

Earnings Flash (LEGN) Legend Biotech Corporation Posts Q2 Adjusted Net Income $0.16 per Share

Legend Biotech Corporation reported an adjusted net income of $0.16 per share for the second quarter of 2026. This financial announcement was made on August 11, 2026, and also included a reported Q2 revenue of $387.5 million, surpassing FactSet's estimate of $356.0 million. The …

Fortress Biotech Inc (FBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates

Atara Biotherapeutics (ATRA) Earnings Date and Reports 2026 $ATRA

SAB Biotherapeutics Inc (SABS) Earnings Forecast: Future EPS & Revenue Growth Estimates

BIOEN Hisse Yorumları (BIOTREND CEVRE VE ENERJI Güncel Yorumlar)

Riot Platforms, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:RIOT) 2026-08-11

Weekly Recap: Q3 RevPAR boost and $0.73 quarterly dividend declared

Marriott International (MAR) reported a Q3 RevPAR boost, partly due to the World Cup, but anticipates a slight dip in Q4 because of U.S. midterms and Middle East issues. The company also announced a record 629,000-room pipeline, added 17,900 net rooms, and declared a …

Lakefront Biotherapeutics NV Reports Earnings Results for the Half Year Ended June 30, 2026

Lakefront Biotherapeutics NV announced its earnings results for the half year ended June 30, 2026. The company reported a significant decrease in revenue to EUR 18.6 million from EUR 140.3 million a year ago, but achieved a net income of EUR 16.6 million, a …

Riot Platforms Inc (RIOT) (Q2 2026) Earnings Call Highlights: Strategic Pivot to AI Data ...

This article first appeared on GuruFocus. Total Revenue: $174 million, a 14% increase year-over-year. GAAP Net Loss: $237 million, or $0.68 per diluted share. Adjusted EBITDA Loss: $70 million. Data Center Segment Revenue: $23 million, including $4.9 million in operating lease revenue. Operating Lease …

Lakefront Biotherapeutics H1 Net Profit From Continuing Operations EUR15.8 Mln

Hong Kong Market Midday Commentary | All three major indices declined, with the Hang Seng Tech Index down 1.27%; tech and internet stocks fell, with Kuaishou and JD.com each dropping nearly 3%; biotech stocks rose, as GenScript Biotech surged over 8

Riot Platforms stock jumps 25% after-hours on $9.1 billion AI deal reportedly with Anthropic

Riot Platforms announced a 20-year, $9.1 billion data center lease agreement with an unnamed "leading frontier AI lab," which Bloomberg reported to be Anthropic. This deal, along with a prior agreement with AMD, brings Riot's long-term contracted revenue to $9.8 billion. Following the announcement, …